ArticleFrontiers in immunology2026
Diagnostic value of the kappa free light chain index in multiple sclerosis under the 2024 CSF positivity criterion: a multicentre study in oligoclonal band-negative patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The kappa free light chain index (κ-FLC) has been established as an alternative to oligoclonal bands (OCB) for defining cerebrospinal fluid (CSF) positivity, which can contribute to a multiple sclerosis (MS) diagnosis by the 2024 revised MS diagnostic criteria. This study aimed to evaluate the contribution of the κ-FLC index to the diagnosis of MS, through the CSF positivity criterion, in OCB-negative patients. Methods: OCB-negative patients, diagnosed with MS at any time according to the 2017 McDonald criteria, were included in this multicentre retrospective study. CSF positivity was defined by a κ-FLC index ≥ 6.1. Results: Among 141 enrolled patients, 117(83%) patients had measurable CSF κ-FLC, with a median κ-FLC index of 7.2 (IQR: 4.5-12.7) and 61 patients (43%) had a positive (≥ 6.1) κ-FLC index. A MS diagnosis was met at the time of the lumbar puncture in 102 patients, through the fulfilment of both the 2017 dissemination in space (DIS) and time (DIT) criteria. Among the remaining 39 patients, MS diagnosis was met following a relapse in 11 (28%) and based on follow-up MRI findings in 28 patients (72%). Among the 34 patients meeting DIS but not DIT criteria, 16 (47%) had a κ-FLC index ≥ 6.1. Considering the contribution of the κ-FLC index to the CSF positivity criterion, a MS diagnosis could have been anticipated in these patients by a median of 4.9 months (IQR: 1.8-14.1). Conclusion: In the context of the CSF positivity criterion of the revised 2024 MS diagnostic criteria, the κ-FLC index may contribute to an earlier MS diagnosis in OCB-negative patients fulfilling the DIS but not the DIT criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.